| Year |
Citation |
Score |
| 2024 |
Kader T, Lin JR, Hug CB, Coy S, Chen YA, de Bruijn I, Shih N, Jung E, Pelletier RJ, Lopez Leon M, Mingo G, Omran DK, Lee JS, Yapp C, Satravada BA, ... ... Drapkin R, et al. Multimodal Spatial Profiling Reveals Immune Suppression and Microenvironment Remodeling in Fallopian Tube Precursors to High-Grade Serous Ovarian Carcinoma. Cancer Discovery. PMID 39704522 DOI: 10.1158/2159-8290.CD-24-1366 |
0.32 |
|
| 2024 |
Madan E, Palma AM, Vudatha V, Kumar A, Bhoopathi P, Wilhelm J, Bernas T, Martin PC, Bilolikar G, Gogna A, Peixoto ML, Dreier I, Araujo TF, Garre E, Gustafsson A, ... ... Drapkin R, et al. Ovarian tumor cells gain competitive advantage by actively reducing the cellular fitness of microenvironment cells. Nature Biotechnology. PMID 39653752 DOI: 10.1038/s41587-024-02453-3 |
0.482 |
|
| 2024 |
Knarr MJ, Moon J, Rawat P, DiFeo A, Hoon DSB, Drapkin R. Repurposing colforsin daropate to treat MYC-driven high-grade serous ovarian carcinomas. Science Signaling. 17: eado8303. PMID 39561220 DOI: 10.1126/scisignal.ado8303 |
0.406 |
|
| 2024 |
Devenport JM, Tran T, Harris BR, Fingerman DF, DeWeerd RA, Elkhidir L, LaVigne D, Fuh K, Sun L, Bednarski JJ, Drapkin R, Mullen M, Green AM. APOBEC3A drives metastasis of high-grade serous ovarian cancer by altering epithelial-to-mesenchymal transition. Biorxiv : the Preprint Server For Biology. PMID 39553968 DOI: 10.1101/2024.10.25.620297 |
0.453 |
|
| 2024 |
Stojanovic L, Abbotts R, Tripathi K, Coon CM, Rajendran S, Farid EA, Hostetter G, Guarnieri JW, Wallace DC, Liu S, Wan J, Calendo G, Marker R, Gohari Z, Inayatullah MMA, ... ... Drapkin R, et al. ZNFX1 is a Novel Master Regulator in Epigenetically-induced Pathogen Mimicry and Inflammasome Signaling in Cancer. Biorxiv : the Preprint Server For Biology. PMID 39484607 DOI: 10.1101/2024.10.18.618659 |
0.336 |
|
| 2024 |
Kader T, Lin JR, Hug C, Coy S, Chen YA, de Bruijn I, Shih N, Jung E, Pelletier RJ, Leon ML, Mingo G, Omran DK, Lee JS, Yapp C, Satravada BA, ... ... Drapkin R, et al. Multimodal Spatial Profiling Reveals Immune Suppression and Microenvironment Remodeling in Fallopian Tube Precursors to High-Grade Serous Ovarian Carcinoma. Biorxiv : the Preprint Server For Biology. PMID 39386723 DOI: 10.1101/2024.09.25.615007 |
0.32 |
|
| 2024 |
Medina JE, Annapragada AV, Lof P, Short S, Bartolomucci AL, Mathios D, Koul S, Niknafs N, Noe M, Foda ZH, Bruhm DC, Hruban C, Vulpescu NA, Jung E, Dua R, ... ... Drapkin R, et al. Early detection of ovarian cancer using cell-free DNA fragmentomes and protein biomarkers. Cancer Discovery. PMID 39345137 DOI: 10.1158/2159-8290.CD-24-0393 |
0.42 |
|
| 2024 |
Garcia GL, Orellana T, Gorecki G, Frisbie LG, Baruwal R, Goldfield E, Beddows I, MacFawn IP, Britt AK, Hale MM, Shen H, Buckanovich R, Finkel T, Drapkin R, Soong TR, et al. Stromal mediated DNA damage promotes high grade serous ovarian cancer initiation. Biorxiv : the Preprint Server For Biology. PMID 38853994 DOI: 10.1101/2024.05.23.595550 |
0.474 |
|
| 2024 |
Reavis HD, Gysler SM, McKenney GB, Knarr M, Lusk HJ, Rawat P, Rendulich HS, Mitchell MA, Berger DS, Moon JS, Ryu S, Mainigi M, Iwanicki MP, Hoon DS, Sanchez LM, ... Drapkin R, et al. Norepinephrine induces anoikis resistance in high-grade serous ovarian cancer precursor cells. Jci Insight. PMID 38271085 DOI: 10.1172/jci.insight.170961 |
0.325 |
|
| 2023 |
Bustos MA, Yokoe T, Shoji Y, Kobayashi Y, Mizuno S, Murakami T, Zhang X, Sekhar SC, Kim S, Ryu S, Knarr M, Vasilev SA, DiFeo A, Drapkin R, Hoon DSB. MiR-181a targets STING to drive PARP inhibitor resistance in BRCA- mutated triple-negative breast cancer and ovarian cancer. Cell & Bioscience. 13: 200. PMID 37932806 DOI: 10.1186/s13578-023-01151-y |
0.348 |
|
| 2023 |
Kinose Y, Xu H, Kim H, Kumar S, Shan X, George E, Wang X, Medvedev S, Ferman B, Gitto SB, Whicker M, D'Andrea K, Wubbenhorst B, Hallberg D, O'Connor M, ... ... Drapkin R, et al. Dual blockade of BRD4 and ATR/WEE1 pathways exploits loss in clear cell ovarian cancer. Research Square. PMID 37841875 DOI: 10.21203/rs.3.rs-3314138/v1 |
0.382 |
|
| 2023 |
Taylor MS, Wu C, Fridy PC, Zhang SJ, Senussi Y, Wolters JC, Cajuso T, Cheng WC, Heaps JD, Miller BD, Mori K, Cohen L, Jiang H, Molloy KR, Chait BT, ... ... Drapkin R, et al. Ultrasensitive detection of circulating LINE-1 ORF1p as a specific multi-cancer biomarker. Cancer Discovery. PMID 37698949 DOI: 10.1158/2159-8290.CD-23-0313 |
0.396 |
|
| 2023 |
Ferrari AJ, Rawat P, Rendulich HS, Annapragada AV, Kinose Y, Zhang X, Devins K, Budina A, Scharpf RB, Mitchell MA, Tanyi JL, Morgan MA, Schwartz LE, Soong TR, Velculescu VE, ... Drapkin R, et al. H2Bub1 loss is an early contributor to clear cell ovarian cancer progression. Jci Insight. 8. PMID 37345659 DOI: 10.1172/jci.insight.164995 |
0.38 |
|
| 2023 |
Nameki RA, Chang H, Yu P, Abbasi F, Lin X, Reddy J, Haro M, Fonseca MA, Freedman ML, Drapkin R, Corona RI, Lawrenson K. Rewiring of master transcription factor cistromes during high-grade serous ovarian cancer development. Biorxiv : the Preprint Server For Biology. PMID 37090516 DOI: 10.1101/2023.04.11.536378 |
0.333 |
|
| 2023 |
Zhou W, Liu H, Yuan Z, Zundell J, Towers M, Lin J, Lombardi S, Nie H, Murphy B, Yang T, Wang C, Liao L, Goldman AR, Kannan T, Kossenkov AV, ... Drapkin R, et al. Targeting the mevalonate pathway suppresses ARID1A-inactivated cancers by promoting pyroptosis. Cancer Cell. PMID 36963401 DOI: 10.1016/j.ccell.2023.03.002 |
0.306 |
|
| 2023 |
Taylor MS, Wu C, Fridy PC, Senussi Y, Cheng WC, Heaps J, Mori K, Cohen L, Molloy KR, Chait BT, Goggins M, Bhan I, Franses JW, Yang X, Taplin ME, ... ... Drapkin R, et al. Ultrasensitive detection of circulating LINE-1 ORF1p as a specific multi-cancer biomarker. Biorxiv : the Preprint Server For Biology. PMID 36747644 DOI: 10.1101/2023.01.25.525462 |
0.377 |
|
| 2023 |
Sato S, Gillette M, de Santiago PR, Kuhn E, Burgess M, Doucette K, Feng Y, Mendez-Dorantes C, Ippoliti PJ, Hobday S, Mitchell MA, Doberstein K, Gysler SM, Hirsch MS, Schwartz L, ... ... Drapkin R, et al. LINE-1 ORF1p as a candidate biomarker in high grade serous ovarian carcinoma. Scientific Reports. 13: 1537. PMID 36707610 DOI: 10.1038/s41598-023-28840-5 |
0.647 |
|
| 2022 |
Doberstein K, Spivak R, Reavis HD, Hooda J, Feng Y, Kroeger PT, Stuckelberger S, Mills GB, Devins KM, Schwartz LE, Iwanicki MP, Fogel M, Altevogt P, Drapkin R. L1CAM is required for early dissemination of fallopian tube carcinoma precursors to the ovary. Communications Biology. 5: 1362. PMID 36509990 DOI: 10.1038/s42003-022-04314-8 |
0.325 |
|
| 2022 |
Banerjee S, Drapkin R, Richardson DL, Birrer M. Targeting NaPi2b in ovarian cancer. Cancer Treatment Reviews. 112: 102489. PMID 36446254 DOI: 10.1016/j.ctrv.2022.102489 |
0.447 |
|
| 2022 |
Madan E, Palma AM, Vudatha V, Trevino JG, Natarajan KN, Winn RA, Won KJ, Graham TA, Drapkin R, McDonald SA, Fisher PB, Gogna R. Cell competition in carcinogenesis. Cancer Research. PMID 36214625 DOI: 10.1158/0008-5472.CAN-22-2217 |
0.37 |
|
| 2022 |
Chaves-Moreira D, Mitchell MA, Arruza C, Rawat P, Sidoli S, Nameki R, Reddy J, Corona RI, Afeyan LK, Klein IA, Ma S, Winterhoff B, Konecny GE, Garcia BA, Brady DC, ... ... Drapkin R, et al. The transcription factor PAX8 promotes angiogenesis in ovarian cancer through interaction with SOX17. Science Signaling. 15: eabm2496. PMID 35380877 DOI: 10.1126/scisignal.abm2496 |
0.447 |
|
| 2021 |
Cunningham JM, Winham SJ, Wang C, Weigelt B, Fu Z, Armasu SM, McCauley BM, Brand AH, Chiew YE, Elishaev E, Gourley C, Kennedy CJ, Laslvic A, Lester J, Piskorz A, ... ... Drapkin R, et al. DNA Methylation Profiles of Ovarian Clear Cell Carcinoma. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. PMID 34697060 DOI: 10.1158/1055-9965.EPI-21-0677 |
0.36 |
|
| 2021 |
Xu H, George E, Kinose Y, Kim H, Shah JB, Peake JD, Ferman B, Medvedev S, Murtha T, Barger CJ, Devins KM, D'Andrea K, Wubbenhorst B, Schwartz LE, Hwang WT, ... ... Drapkin R, et al. copy number is a biomarker for response to combination WEE1-ATR inhibition in ovarian and endometrial cancer models. Cell Reports. Medicine. 2: 100394. PMID 34622231 DOI: 10.1016/j.xcrm.2021.100394 |
0.352 |
|
| 2021 |
Lecker LS, Berlato C, Maniati E, Delaine-Smith R, Pearce OMT, Heath O, Nichols SJ, Trevisan C, Novak M, McDermott J, Brenton JD, Cutillas PR, Rajeeve V, Hennino A, Drapkin R, et al. TGFBI production by macrophages contributes to an immunosuppressive microenvironment in ovarian cancer. Cancer Research. PMID 34561272 DOI: 10.1158/0008-5472.CAN-21-0536 |
0.334 |
|
| 2021 |
Wu S, Fukumoto T, Lin J, Nacarelli T, Wang Y, Ong D, Liu H, Fatkhutdinov N, Zundell JA, Karakashev S, Zhou W, Schwartz LE, Tang HY, Drapkin R, Liu Q, et al. Targeting glutamine dependence through GLS1 inhibition suppresses ARID1A-inactivated clear cell ovarian carcinoma. Nature Cancer. 2: 189-200. PMID 34085048 DOI: 10.1038/s43018-020-00160-x |
0.32 |
|
| 2021 |
Gysler SM, Drapkin R. Tumor innervation: peripheral nerves take control of the tumor microenvironment. The Journal of Clinical Investigation. 131. PMID 34060481 DOI: 10.1172/JCI147276 |
0.314 |
|
| 2021 |
Barger CJ, Chee L, Albahrani M, Munoz-Trujillo C, Boghean L, Branick C, Odunsi K, Drapkin R, Zou L, Karpf AR. Co-regulation and function of / bidirectional genes in cancer. Elife. 10. PMID 33890574 DOI: 10.7554/eLife.55070 |
0.437 |
|
| 2021 |
Mauro LJ, Seibel MI, Diep CH, Spartz A, Perez Kerkvliet C, Singhal H, Swisher EM, Schwartz LE, Drapkin R, Saini S, Sesay F, Litovchick L, Lange CA. Progesterone Receptors Promote Quiescence & Ovarian Cancer Cell Phenotypes via DREAM in p53-Mutant Fallopian Tube Models. The Journal of Clinical Endocrinology and Metabolism. PMID 33755733 DOI: 10.1210/clinem/dgab195 |
0.314 |
|
| 2021 |
Tangri A, Lighty K, Loganathan J, Mesmar F, Podicheti R, Zhang C, Iwanicki M, Drapkin R, Nakshatri H, Mitra S. Deubiquitinase UCHL1 Maintains Protein Homeostasis through the PSMA7-APEH-Proteasome Axis in High-Grade Serous Ovarian Carcinoma. Molecular Cancer Research : McR. PMID 33753553 DOI: 10.1158/1541-7786.MCR-20-0883 |
0.38 |
|
| 2021 |
Burston HE, Kent OA, Communal L, Udaskin ML, Sun RX, Brown KR, Jung E, Francis KE, La Rose J, Lowitz JK, Drapkin R, Mes-Masson AM, Rottapel R. Inhibition of relaxin autocrine signaling confers therapeutic vulnerability in ovarian cancer. The Journal of Clinical Investigation. PMID 33561012 DOI: 10.1172/JCI142677 |
0.407 |
|
| 2021 |
Ferrari AJ, Drapkin R, Gogna R. Cell Fitness: More Than Push-Ups. International Journal of Molecular Sciences. 22. PMID 33430180 DOI: 10.3390/ijms22020518 |
0.387 |
|
| 2021 |
Chaves-Moreira D, Morin PJ, Drapkin R. Unraveling the Mysteries of PAX8 in Reproductive Tract Cancers. Cancer Research. 81: 806-810. PMID 33361393 DOI: 10.1158/0008-5472.CAN-20-3173 |
0.433 |
|
| 2020 |
Lv X, He C, Huang C, Hua G, Chen X, Timm BK, Maclin VM, Haggerty AA, Aust SK, Golden DM, Dave BJ, Tseng YA, Chen L, Wang H, Chen P, ... ... Drapkin RI, et al. Reprogramming of Ovarian Granulosa Cells by YAP1 Leads to Development of High-Grade Cancer with Mesenchymal Lineage and Serous Features. Science Bulletin. 65: 1281-1296. PMID 34888112 DOI: 10.1016/j.scib.2020.03.040 |
0.454 |
|
| 2020 |
Pierini S, Tanyi JL, Simpkins F, George E, Uribe-Herranz M, Drapkin R, Burger R, Morgan MA, Facciabene A. Ovarian granulosa cell tumor characterization identifies FOXL2 as an immunotherapeutic target. Jci Insight. 5. PMID 32814714 DOI: 10.1172/jci.insight.136773 |
0.323 |
|
| 2020 |
Kim O, Park EY, Klinkebiel DL, Pack SD, Shin YH, Abdullaev Z, Emerson RE, Coffey DM, Kwon SY, Creighton CJ, Kwon S, Chang EC, Chiang T, Yatsenko AN, Chien J, ... ... Drapkin R, et al. In vivo modeling of metastatic human high-grade serous ovarian cancer in mice. Plos Genetics. 16: e1008808. PMID 32497036 DOI: 10.1371/Journal.Pgen.1008808 |
0.423 |
|
| 2020 |
Suryo Rahmanto Y, Shen W, Shi X, Chen X, Yu Y, Yu ZC, Miyamoto T, Lee MH, Singh V, Asaka R, Shimberg G, Vitolo MI, Martin SS, Wirtz D, Drapkin R, et al. Inactivation of Arid1a in the endometrium is associated with endometrioid tumorigenesis through transcriptional reprogramming. Nature Communications. 11: 2717. PMID 32483112 DOI: 10.1038/S41467-020-16416-0 |
0.359 |
|
| 2020 |
Ding B, Yuan F, Damle PK, Litovchick L, Drapkin R, Grossman SR. CtBP determines ovarian cancer cell fate through repression of death receptors. Cell Death & Disease. 11: 286. PMID 32332713 DOI: 10.1038/S41419-020-2455-7 |
0.411 |
|
| 2020 |
Reavis HD, Drapkin R. The tubal epigenome - An emerging target for ovarian cancer. Pharmacology & Therapeutics. 210: 107524. PMID 32197795 DOI: 10.1016/j.pharmthera.2020.107524 |
0.425 |
|
| 2020 |
Maniati E, Berlato C, Gopinathan G, Heath O, Kotantaki P, Lakhani A, McDermott J, Pegrum C, Delaine-Smith RM, Pearce OMT, Hirani P, Joy JD, Szabova L, Perets R, Sansom OJ, ... Drapkin R, et al. Mouse Ovarian Cancer Models Recapitulate the Human Tumor Microenvironment and Patient Response to Treatment. Cell Reports. 30: 525-540.e7. PMID 31940494 DOI: 10.1016/j.celrep.2019.12.034 |
0.341 |
|
| 2019 |
Lawrenson K, Fonseca MAS, Liu AY, Segato Dezem F, Lee JM, Lin X, Corona RI, Abbasi F, Vavra KC, Dinh HQ, Gill NK, Seo JH, Coetzee S, Lin YG, Pejovic T, ... ... Drapkin R, et al. A Study of High-Grade Serous Ovarian Cancer Origins Implicates the SOX18 Transcription Factor in Tumor Development. Cell Reports. 29: 3726-3735.e4. PMID 31825847 DOI: 10.1016/J.Celrep.2019.10.122 |
0.364 |
|
| 2019 |
Bai S, Zhu W, Coffman L, Vlad A, Schwartz LE, Elishaev E, Drapkin R, Buckanovich RJ. CD105 Is Expressed in Ovarian Cancer Precursor Lesions and Is Required for Metastasis to the Ovary. Cancers. 11. PMID 31684072 DOI: 10.3390/Cancers11111710 |
0.324 |
|
| 2019 |
Reavis H, Drapkin R. H2Bub1: Guardian of chromatin accessibility in ovarian cancer. Oncoscience. 6: 349-350. PMID 31608296 DOI: 10.18632/oncoscience.484 |
0.373 |
|
| 2019 |
Chui MH, Doodnauth SA, Erdmann N, Tiedemann RE, Sircoulomb F, Drapkin R, Shaw P, Rottapel R. Chromosomal instability and mTORC1 activation through PTEN loss contribute to proteotoxic stress in ovarian carcinoma. Cancer Research. PMID 31530568 DOI: 10.1158/0008-5472.Can-18-3029 |
0.385 |
|
| 2019 |
Zhao B, Lin J, Rong L, Wu S, Deng Z, Fatkhutdinov N, Zundell J, Fukumoto T, Liu Q, Kossenkov A, Jean S, Cadungog MG, Borowsky ME, Drapkin R, Lieberman PM, et al. ARID1A promotes genomic stability through protecting telomere cohesion. Nature Communications. 10: 4067. PMID 31492885 DOI: 10.1038/S41467-019-12037-4 |
0.334 |
|
| 2019 |
Bast RC, Matulonis UA, Sood AK, Ahmed AA, Amobi AE, Balkwill FR, Wielgos-Bonvallet M, Bowtell DDL, Brenton JD, Brugge JS, Coleman RL, Draetta GF, Doberstein K, Drapkin RI, Eckert MA, et al. Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference. Cancer. PMID 30835824 DOI: 10.1002/Cncr.32004 |
0.354 |
|
| 2018 |
Hooda J, Novak M, Salomon MP, Matsuba C, Ramos RI, MacDuffie E, Song M, Hirsch MS, Lester J, Parkash V, Karlan BY, Oren M, Hoon DS, Drapkin R. Early loss of Histone H2B monoubiquitylation alters chromatin accessibility and activates key immune pathways that facilitate progression of ovarian cancer. Cancer Research. PMID 30563893 DOI: 10.1158/0008-5472.Can-18-2297 |
0.363 |
|
| 2018 |
Papp E, Hallberg D, Konecny GE, Bruhm DC, Adleff V, Noë M, Kagiampakis I, Palsgrove D, Conklin D, Kinose Y, White JR, Press MF, Drapkin R, Easwaran H, Baylin SB, et al. Integrated Genomic, Epigenomic, and Expression Analyses of Ovarian Cancer Cell Lines. Cell Reports. 25: 2617-2633. PMID 30485824 DOI: 10.1016/J.Celrep.2018.10.096 |
0.425 |
|
| 2018 |
Barger CJ, Zhang W, Sharma A, Chee L, James SR, Kufel CN, Miller A, Meza J, Drapkin R, Odunsi K, Klinkebiel D, Karpf AR. Expression of the POTE gene family in human ovarian cancer. Scientific Reports. 8: 17136. PMID 30459449 DOI: 10.1038/s41598-018-35567-1 |
0.424 |
|
| 2018 |
Singha B, Harper SL, Goldman AR, Bitler BG, Aird KM, Borowsky ME, Cadungog MG, Liu Q, Zhang R, Jean S, Drapkin R, Speicher DW. CLIC1 and CLIC4 complement CA125 as a diagnostic biomarker panel for all subtypes of epithelial ovarian cancer. Scientific Reports. 8: 14725. PMID 30282979 DOI: 10.1038/S41598-018-32885-2 |
0.314 |
|
| 2018 |
Elias KM, Tsantoulis P, Tille JC, Vitonis A, Doyle LA, Hornick JL, Kaya G, Barnes L, Cramer DW, Puppa G, Stuckelberger S, Hooda J, Dietrich PY, Goggins M, Kerr CL, ... ... Drapkin R, et al. Primordial germ cells as a potential shared cell of origin for mucinous cystic neoplasms of the pancreas and mucinous ovarian tumors. The Journal of Pathology. PMID 30229909 DOI: 10.1002/path.5161 |
0.344 |
|
| 2018 |
Han C, Bellone S, Siegel ER, Altwerger G, Menderes G, Bonazzoli E, Egawa-Takata T, Pettinella F, Bianchi A, Riccio F, Zammataro L, Yadav G, Marto JA, Penet MF, Levine DA, ... Drapkin R, et al. A novel multiple biomarker panel for the early detection of high-grade serous ovarian carcinoma. Gynecologic Oncology. PMID 29572027 DOI: 10.1016/J.Ygyno.2018.03.050 |
0.381 |
|
| 2018 |
Stuckelberger S, Drapkin R. Precious GEMMs: emergence of faithful models for ovarian cancer research. The Journal of Pathology. 245: 129-131. PMID 29493783 DOI: 10.1002/path.5065 |
0.375 |
|
| 2018 |
Karakashev S, Zhu H, Wu S, Yokoyama Y, Bitler BG, Park PH, Lee JH, Kossenkov AV, Gaonkar KS, Yan H, Drapkin R, Conejo-Garcia JR, Speicher DW, Ordog T, Zhang R. CARM1-expressing ovarian cancer depends on the histone methyltransferase EZH2 activity. Nature Communications. 9: 631. PMID 29434212 DOI: 10.1038/S41467-018-03031-3 |
0.444 |
|
| 2017 |
Labidi-Galy SI, Papp E, Hallberg D, Niknafs N, Adleff V, Noe M, Bhattacharya R, Novak M, Jones S, Phallen J, Hruban CA, Hirsch MS, Lin DI, Schwartz L, Maire CL, ... ... Drapkin R, et al. High grade serous ovarian carcinomas originate in the fallopian tube. Nature Communications. 8: 1093. PMID 29061967 DOI: 10.1038/S41467-017-00962-1 |
0.409 |
|
| 2017 |
Zervantonakis IK, Iavarone C, Chen HY, Selfors LM, Palakurthi S, Liu JF, Drapkin R, Matulonis U, Leverson JD, Sampath D, Mills GB, Brugge JS. Systems analysis of apoptotic priming in ovarian cancer identifies vulnerabilities and predictors of drug response. Nature Communications. 8: 365. PMID 28848242 DOI: 10.1038/S41467-017-00263-7 |
0.329 |
|
| 2017 |
Sarkar S, Bristow CA, Dey P, Rai K, Perets R, Ramirez-Cardenas A, Malasi S, Huang-Hobbs E, Haemmerle M, Wu SY, McGuire M, Protopopov A, Jiang S, Liu JF, Hirsch MS, ... ... Drapkin R, et al. PRKCI promotes immune suppression in ovarian cancer. Genes & Development. PMID 28698296 DOI: 10.1101/Gad.296640.117 |
0.463 |
|
| 2017 |
Samimi G, Bernardini MQ, Brody LC, Caga-Anan CF, Campbell IG, Chenevix-Trench G, Couch FJ, Dean M, de Hullu JA, Domchek SM, Drapkin R, Spencer Feigelson H, Friedlander M, Gaudet MM, Harmsen MG, et al. Traceback: A Proposed Framework to Increase Identification and Genetic Counseling of BRCA1 and BRCA2 Mutation Carriers Through Family-Based Outreach. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2016703439. PMID 28398847 DOI: 10.1200/Jco.2016.70.3439 |
0.312 |
|
| 2017 |
Medrano M, Communal L, Brown KR, Iwanicki M, Normand J, Paterson J, Sircoulomb F, Krzyzanowski P, Novak M, Doodnauth SA, Saiz FS, Cullis J, Al-Awar R, Neel BG, McPherson J, ... Drapkin R, et al. Interrogation of Functional Cell-Surface Markers Identifies CD151 Dependency in High-Grade Serous Ovarian Cancer. Cell Reports. 18: 2343-2358. PMID 28273451 DOI: 10.1016/J.Celrep.2017.02.028 |
0.342 |
|
| 2017 |
George E, Kim H, Krepler C, Wenz B, Makvandi M, Tanyi JL, Brown E, Zhang R, Brafford P, Jean S, Mach RH, Lu Y, Mills GB, Herlyn M, Morgan M, ... ... Drapkin R, et al. A patient-derived-xenograft platform to study BRCA-deficient ovarian cancers. Jci Insight. 2: e89760. PMID 28097235 DOI: 10.1172/Jci.Insight.89760 |
0.367 |
|
| 2017 |
Kroeger PT, Drapkin R. Pathogenesis and heterogeneity of ovarian cancer. Current Opinion in Obstetrics & Gynecology. 29: 26-34. PMID 27898521 DOI: 10.1097/GCO.0000000000000340 |
0.419 |
|
| 2016 |
Au-Yeung G, Lang F, Azar WJ, Mitchell C, Jarman KE, Lackovic K, Aziz D, Cullinane C, Pearson RB, Mileshkin L, Rischin D, Karst AM, Drapkin R, Etemadmoghadam D, Bowtell DD. Selective targeting of Cyclin E1 amplified high grade serous ovarian cancer by cyclin-dependent kinase 2 and AKT inhibition. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27663592 DOI: 10.1158/1078-0432.CCR-16-0620 |
0.335 |
|
| 2016 |
Elias KM, Emori MM, Westerling T, Long H, Budina-Kolomets A, Li F, MacDuffie E, Davis MR, Holman A, Lawney B, Freedman ML, Quackenbush J, Brown M, Drapkin R. Epigenetic remodeling regulates transcriptional changes between ovarian cancer and benign precursors. Jci Insight. 1. PMID 27617304 DOI: 10.1172/Jci.Insight.87988 |
0.554 |
|
| 2016 |
Liu JF, Palakurthi S, Zeng Q, Zhou S, Ivanova E, Huang W, Zervantonakis IK, Selfors LM, Shen Y, Pritchard CC, Zheng M, Adleff V, Papp E, Piao H, Novak M, ... ... Drapkin R, et al. Establishment of patient-derived tumor xenograft models of epithelial ovarian cancer for pre-clinical evaluation of novel therapeutics. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27573169 DOI: 10.1158/1078-0432.Ccr-16-1237 |
0.56 |
|
| 2016 |
Wang S, Blois A, El Rayes T, Liu JF, Hirsch MS, Gravdal K, Palakurthi S, Bielenberg DR, Akslen LA, Drapkin R, Mittal V, Watnick RS. Development of a prosaposin-derived therapeutic cyclic peptide that targets ovarian cancer via the tumor microenvironment. Science Translational Medicine. 8: 329ra34. PMID 26962158 DOI: 10.1126/Scitranslmed.Aad5653 |
0.365 |
|
| 2015 |
Rupaimoole R, Lee J, Haemmerle M, Ling H, Previs RA, Pradeep S, Wu SY, Ivan C, Ferracin M, Dennison JB, Millward NM, Nagaraja AS, Gharpure KM, McGuire M, Sam N, ... ... Drapkin RI, et al. Long Noncoding RNA Ceruloplasmin Promotes Cancer Growth by Altering Glycolysis. Cell Reports. PMID 26686630 DOI: 10.1016/J.Celrep.2015.11.047 |
0.428 |
|
| 2015 |
Feng Y, Doberstein K, Drapkin R. Elafin: a double agent in breast and ovarian cancer. Oncoscience. 2: 793-4. PMID 26682248 |
0.347 |
|
| 2015 |
Bowtell DD, Böhm S, Ahmed AA, Aspuria PJ, Bast RC, Beral V, Berek JS, Birrer MJ, Blagden S, Bookman MA, Brenton JD, Chiappinelli KB, Martins FC, Coukos G, Drapkin R, et al. Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nature Reviews. Cancer. 15: 668-79. PMID 26493647 DOI: 10.1038/Nrc4019 |
0.371 |
|
| 2015 |
Elias KM, Emori MM, Papp E, MacDuffie E, Konecny GE, Velculescu VE, Drapkin R. Beyond genomics: Critical evaluation of cell line utility for ovarian cancer research. Gynecologic Oncology. 139: 97-103. PMID 26321251 DOI: 10.1016/J.Ygyno.2015.08.017 |
0.353 |
|
| 2015 |
Patch AM, Christie EL, Etemadmoghadam D, Garsed DW, George J, Fereday S, Nones K, Cowin P, Alsop K, Bailey PJ, Kassahn KS, Newell F, Quinn MC, Kazakoff S, Quek K, ... ... Drapkin R, et al. Whole-genome characterization of chemoresistant ovarian cancer. Nature. 521: 489-94. PMID 26017449 DOI: 10.1038/Nature14410 |
0.303 |
|
| 2015 |
Vathipadiekal V, Wang V, Wei W, Waldron L, Drapkin R, Gillette M, Skates S, Birrer M. Creation of a Human Secretome: A Novel Composite Library of Human Secreted Proteins: Validation Using Ovarian Cancer Gene Expression Data and a Virtual Secretome Array. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 4960-9. PMID 25944803 DOI: 10.1158/1078-0432.Ccr-14-3173 |
0.387 |
|
| 2015 |
Coetzee SG, Shen HC, Hazelett DJ, Lawrenson K, Kuchenbaecker K, Tyrer J, Rhie SK, Levanon K, Karst A, Drapkin R, Ramus SJ, Couch FJ, Offit K, Chenevix-Trench G, et al. Cell-type-specific enrichment of risk-associated regulatory elements at ovarian cancer susceptibility loci. Human Molecular Genetics. 24: 3595-607. PMID 25804953 DOI: 10.1093/Hmg/Ddv101 |
0.399 |
|
| 2015 |
Montero J, Sarosiek KA, DeAngelo JD, Maertens O, Ryan J, Ercan D, Piao H, Horowitz NS, Berkowitz RS, Matulonis U, Jänne PA, Amrein PC, Cichowski K, Drapkin R, Letai A. Drug-induced death signaling strategy rapidly predicts cancer response to chemotherapy. Cell. 160: 977-89. PMID 25723171 DOI: 10.1016/J.Cell.2015.01.042 |
0.541 |
|
| 2015 |
Baratta MG, Schinzel AC, Zwang Y, Bandopadhayay P, Bowman-Colin C, Kutt J, Curtis J, Piao H, Wong LC, Kung AL, Beroukhim R, Bradner JE, Drapkin R, Hahn WC, Liu JF, et al. An in-tumor genetic screen reveals that the BET bromodomain protein, BRD4, is a potential therapeutic target in ovarian carcinoma. Proceedings of the National Academy of Sciences of the United States of America. 112: 232-7. PMID 25535366 DOI: 10.1073/Pnas.1422165112 |
0.702 |
|
| 2014 |
Emori MM, Drapkin R. The hormonal composition of follicular fluid and its implications for ovarian cancer pathogenesis. Reproductive Biology and Endocrinology : Rb&E. 12: 60. PMID 24997727 DOI: 10.1186/1477-7827-12-60 |
0.348 |
|
| 2014 |
Davidowitz RA, Selfors LM, Iwanicki MP, Elias KM, Karst A, Piao H, Ince TA, Drage MG, Dering J, Konecny GE, Matulonis U, Mills GB, Slamon DJ, Drapkin R, Brugge JS. Mesenchymal gene program-expressing ovarian cancer spheroids exhibit enhanced mesothelial clearance. The Journal of Clinical Investigation. 124: 2611-25. PMID 24762435 DOI: 10.1172/Jci69815 |
0.467 |
|
| 2014 |
Dunn GP, Cheung HW, Agarwalla PK, Thomas S, Zektser Y, Karst AM, Boehm JS, Weir BA, Berlin AM, Zou L, Getz G, Liu JF, Hirsch M, Vazquez F, Root DE, ... ... Drapkin R, et al. In vivo multiplexed interrogation of amplified genes identifies GAB2 as an ovarian cancer oncogene. Proceedings of the National Academy of Sciences of the United States of America. 111: 1102-7. PMID 24385586 DOI: 10.1073/Pnas.1311909111 |
0.46 |
|
| 2014 |
Karst AM, Jones PM, Vena N, Ligon AH, Liu JF, Hirsch MS, Etemadmoghadam D, Bowtell DD, Drapkin R. Cyclin E1 deregulation occurs early in secretory cell transformation to promote formation of fallopian tube-derived high-grade serous ovarian cancers. Cancer Research. 74: 1141-52. PMID 24366882 DOI: 10.1158/0008-5472.CAN-13-2247 |
0.36 |
|
| 2013 |
Perets R, Wyant GA, Muto KW, Bijron JG, Poole BB, Chin KT, Chen JY, Ohman AW, Stepule CD, Kwak S, Karst AM, Hirsch MS, Setlur SR, Crum CP, Dinulescu DM, ... Drapkin R, et al. Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in Brca;Tp53;Pten models. Cancer Cell. 24: 751-65. PMID 24332043 DOI: 10.1016/j.ccr.2013.10.013 |
0.419 |
|
| 2013 |
Li J, Chen H, Mariani A, Chen D, Klatt E, Podratz K, Drapkin R, Broaddus R, Dowdy S, Jiang SW. HE4 (WFDC2) Promotes Tumor Growth in Endometrial Cancer Cell Lines. International Journal of Molecular Sciences. 14: 6026-43. PMID 23502467 DOI: 10.3390/ijms14036026 |
0.461 |
|
| 2013 |
Sung CK, Li D, Andrews E, Drapkin R, Benjamin T. Promoter methylation of the SALL2 tumor suppressor gene in ovarian cancers. Molecular Oncology. 7: 419-27. PMID 23273547 DOI: 10.1016/J.Molonc.2012.11.005 |
0.367 |
|
| 2013 |
Verhaak RG, Tamayo P, Yang JY, Hubbard D, Zhang H, Creighton CJ, Fereday S, Lawrence M, Carter SL, Mermel CH, Kostic AD, Etemadmoghadam D, Saksena G, Cibulskis K, Duraisamy S, ... ... Drapkin R, et al. Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. The Journal of Clinical Investigation. 123: 517-25. PMID 23257362 DOI: 10.1172/Jci65833 |
0.312 |
|
| 2013 |
O'Neal RL, Nam KT, LaFleur BJ, Barlow B, Nozaki K, Lee HJ, Kim WH, Yang HK, Shi C, Maitra A, Montgomery E, Washington MK, El Rifai W, Drapkin RI, Goldenring JR. Human epididymis protein 4 is up-regulated in gastric and pancreatic adenocarcinomas. Human Pathology. 44: 734-42. PMID 23084584 DOI: 10.1016/J.Humpath.2012.07.017 |
0.34 |
|
| 2012 |
Wang ZC, Birkbak NJ, Culhane AC, Drapkin R, Fatima A, Tian R, Schwede M, Alsop K, Daniels KE, Piao H, Liu J, Etemadmoghadam D, Miron A, Salvesen HB, Mitchell G, et al. Profiles of genomic instability in high-grade serous ovarian cancer predict treatment outcome. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 5806-15. PMID 22912389 DOI: 10.1158/1078-0432.Ccr-12-0857 |
0.315 |
|
| 2012 |
Ren Y, Cheung HW, von Maltzhan G, Agrawal A, Cowley GS, Weir BA, Boehm JS, Tamayo P, Karst AM, Liu JF, Hirsch MS, Mesirov JP, Drapkin R, Root DE, Lo J, et al. Targeted tumor-penetrating siRNA nanocomplexes for credentialing the ovarian cancer oncogene ID4. Science Translational Medicine. 4: 147ra112. PMID 22896676 DOI: 10.1126/Scitranslmed.3003778 |
0.414 |
|
| 2012 |
Bentink S, Haibe-Kains B, Risch T, Fan JB, Hirsch MS, Holton K, Rubio R, April C, Chen J, Wickham-Garcia E, Liu J, Culhane A, Drapkin R, Quackenbush J, Matulonis UA. Angiogenic mRNA and microRNA gene expression signature predicts a novel subtype of serous ovarian cancer. Plos One. 7: e30269. PMID 22348002 DOI: 10.1371/Journal.Pone.0030269 |
0.455 |
|
| 2012 |
Vermeer PD, Bell M, Lee K, Vermeer DW, Wieking BG, Bilal E, Bhanot G, Drapkin RI, Ganesan S, Klingelhutz AJ, Hendriks WJ, Lee JH. ErbB2, EphrinB1, Src kinase and PTPN13 signaling complex regulates MAP kinase signaling in human cancers. Plos One. 7: e30447. PMID 22279592 DOI: 10.1371/Journal.Pone.0030447 |
0.305 |
|
| 2012 |
Kalogera E, Scholler N, Powless C, Weaver A, Drapkin R, Li J, Jiang SW, Podratz K, Urban N, Dowdy SC. Correlation of serum HE4 with tumor size and myometrial invasion in endometrial cancer Gynecologic Oncology. 124: 270-275. PMID 22037318 DOI: 10.1016/j.ygyno.2011.10.025 |
0.328 |
|
| 2011 |
Karst AM, Drapkin R. The new face of ovarian cancer modeling: better prospects for detection and treatment. F1000 Medicine Reports. 3: 22. PMID 22076125 DOI: 10.3410/M3-22 |
0.367 |
|
| 2011 |
Ni Chonghaile T, Sarosiek KA, Vo TT, Ryan JA, Tammareddi A, Moore Vdel G, Deng J, Anderson KC, Richardson P, Tai YT, Mitsiades CS, Matulonis UA, Drapkin R, Stone R, Deangelo DJ, et al. Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy. Science (New York, N.Y.). 334: 1129-33. PMID 22033517 DOI: 10.1126/Science.1206727 |
0.54 |
|
| 2011 |
Vaughan S, Coward JI, Bast RC, Berchuck A, Berek JS, Brenton JD, Coukos G, Crum CC, Drapkin R, Etemadmoghadam D, Friedlander M, Gabra H, Kaye SB, Lord CJ, Lengyel E, et al. Rethinking ovarian cancer: recommendations for improving outcomes. Nature Reviews. Cancer. 11: 719-25. PMID 21941283 DOI: 10.1038/Nrc3144 |
0.317 |
|
| 2011 |
Matulonis UA, Hirsch M, Palescandolo E, Kim E, Liu J, van Hummelen P, MacConaill L, Drapkin R, Hahn WC. High throughput interrogation of somatic mutations in high grade serous cancer of the ovary. Plos One. 6: e24433. PMID 21931712 DOI: 10.1371/Journal.Pone.0024433 |
0.374 |
|
| 2011 |
Cheung HW, Cowley GS, Weir BA, Boehm JS, Rusin S, Scott JA, East A, Ali LD, Lizotte PH, Wong TC, Jiang G, Hsiao J, Mermel CH, Getz G, Barretina J, ... ... Drapkin R, et al. Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America. 108: 12372-7. PMID 21746896 DOI: 10.1073/Pnas.1109363108 |
0.47 |
|
| 2011 |
Fotheringham S, Levanon K, Drapkin R. Ex vivo culture of primary human fallopian tube epithelial cells. Journal of Visualized Experiments : Jove. PMID 21610668 DOI: 10.3791/2728 |
0.457 |
|
| 2011 |
Mehra K, Mehrad M, Ning G, Drapkin R, McKeon FD, Xian W, Crum CP. STICS, SCOUTs and p53 signatures; a new language for pelvic serous carcinogenesis. Frontiers in Bioscience (Elite Edition). 3: 625-34. PMID 21196340 |
0.37 |
|
| 2010 |
Bouwman P, Aly A, Escandell JM, Pieterse M, Bartkova J, van der Gulden H, Hiddingh S, Thanasoula M, Kulkarni A, Yang Q, Haffty BG, Tommiska J, Blomqvist C, Drapkin R, Adams DJ, et al. 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers. Nature Structural & Molecular Biology. 17: 688-95. PMID 20453858 DOI: 10.1038/Nsmb.1831 |
0.411 |
|
| 2010 |
Sheng Q, Liu X, Fleming E, Yuan K, Piao H, Chen J, Moustafa Z, Thomas RK, Greulich H, Schinzel A, Zaghlul S, Batt D, Ettenberg S, Meyerson M, Schoeberl B, ... ... Drapkin R, et al. An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells. Cancer Cell. 17: 298-310. PMID 20227043 DOI: 10.1016/J.Ccr.2009.12.047 |
0.703 |
|
| 2010 |
Clauss A, Ng V, Liu J, Piao H, Russo M, Vena N, Sheng Q, Hirsch MS, Bonome T, Matulonis U, Ligon AH, Birrer MJ, Drapkin R. Overexpression of elafin in ovarian carcinoma is driven by genomic gains and activation of the nuclear factor kappaB pathway and is associated with poor overall survival. Neoplasia (New York, N.Y.). 12: 161-72. PMID 20126474 DOI: 10.1593/NEO.91542 |
0.434 |
|
| 2009 |
Jarboe EA, Folkins AK, Drapkin R, Ince TA, Agoston ES, Crum CP. Tubal and ovarian pathways to pelvic epithelial cancer: a pathological perspective. Histopathology. 55: 619. PMID 19912369 DOI: 10.1111/j.1365-2559.2009.03408.x |
0.365 |
|
| 2009 |
Karst AM, Drapkin R. Ovarian cancer pathogenesis: a model in evolution. Journal of Oncology. 2010: 932371. PMID 19746182 DOI: 10.1155/2010/932371 |
0.4 |
|
| 2008 |
Levanon K, Crum C, Drapkin R. New insights into the pathogenesis of serous ovarian cancer and its clinical impact Journal of Clinical Oncology. 26: 5284-5293. PMID 18854563 DOI: 10.1200/JCO.2008.18.1107 |
0.38 |
|
| 2008 |
De Nicolo A, Tancredi M, Lombardi G, Flemma CC, Barbuti S, Di Cristofano C, Sobhian B, Bevilacqua G, Drapkin R, Caligo MA. A novel breast cancer-associated BRIP1 (FANCJ/BACH1) germ-line mutation impairs protein stability and function. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 4672-80. PMID 18628483 DOI: 10.1158/1078-0432.CCR-08-0087 |
0.344 |
|
| 2007 |
Crum CP, Drapkin R, Kindelberger D, Medeiros F, Miron A, Lee Y. Lessons from BRCA: the tubal fimbria emerges as an origin for pelvic serous cancer. Clinical Medicine & Research. 5: 35-44. PMID 17456833 DOI: 10.3121/cmr.2007.702 |
0.371 |
|
| 2007 |
Silver DP, Dimitrov SD, Feunteun J, Gelman R, Drapkin R, Lu SD, Shestakova E, Velmurugan S, Denunzio N, Dragomir S, Mar J, Liu X, Rottenberg S, Jonkers J, Ganesan S, et al. Further evidence for BRCA1 communication with the inactive X chromosome. Cell. 128: 991-1002. PMID 17350581 DOI: 10.1016/J.Cell.2007.02.025 |
0.668 |
|
| 2007 |
Erkko H, Xia B, Nikkilä J, Schleutker J, Syrjäkoski K, Mannermaa A, Kallioniemi A, Pylkäs K, Karppinen SM, Rapakko K, Miron A, Sheng Q, Li G, Mattila H, Bell DW, ... ... Drapkin RI, et al. A recurrent mutation in PALB2 in Finnish cancer families Nature. 446: 316-319. PMID 17287723 DOI: 10.1038/Nature05609 |
0.548 |
|
| 2005 |
Drapkin R, von Horsten HH, Lin Y, Mok SC, Crum CP, Welch WR, Hecht JL. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Research. 65: 2162-9. PMID 15781627 DOI: 10.1158/0008-5472.CAN-04-3924 |
0.393 |
|
| 2005 |
Kanellopoulou C, Muljo SA, Kung AL, Ganesan S, Drapkin R, Jenuwein T, Livingston DM, Rajewsky K. Dicer-deficient mouse embryonic stem cells are defective in differentiation and centromeric silencing. Genes & Development. 19: 489-501. PMID 15713842 DOI: 10.1101/Gad.1248505 |
0.611 |
|
| 2004 |
Drapkin R, Crum CP, Hecht JL. Expression of candidate tumor markers in ovarian carcinoma and benign ovary: evidence for a link between epithelial phenotype and neoplasia. Human Pathology. 35: 1014-21. PMID 15297969 DOI: 10.1016/j.humpath.2004.04.014 |
0.307 |
|
| 2004 |
Ganesan S, Silver DP, Drapkin R, Greenberg R, Feunteun J, Livingston DM. Association of BRCA1 with the inactive X chromosome and XIST RNA. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences. 359: 123-8. PMID 15065664 DOI: 10.1098/Rstb.2003.1371 |
0.701 |
|
| 2004 |
Cantor S, Drapkin R, Zhang F, Lin Y, Han J, Pamidi S, Livingston DM. The BRCA1-associated protein BACH1 is a DNA helicase targeted by clinically relevant inactivating mutations Proceedings of the National Academy of Sciences of the United States of America. 101: 2357-2362. PMID 14983014 DOI: 10.1073/Pnas.0308717101 |
0.706 |
|
| 2002 |
Ganesan S, Silver DP, Greenberg RA, Avni D, Drapkin R, Miron A, Mok SC, Randrianarison V, Brodie S, Salstrom J, Rasmussen TP, Klimke A, Marrese C, Marahrens Y, Deng CX, et al. BRCA1 supports XIST RNA concentration on the inactive X chromosome. Cell. 111: 393-405. PMID 12419249 DOI: 10.1016/S0092-8674(02)01052-8 |
0.691 |
|
| Show low-probability matches. |
